A detailed history of Freestone Grove Partners LP transactions in Glaukos Corp stock. As of the latest transaction made, Freestone Grove Partners LP holds 219,810 shares of GKOS stock, worth $18.8 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
219,810
Holding current value
$18.8 Million
% of portfolio
0.17%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$82.27 - $103.29 $18.1 Million - $22.7 Million
219,810 New
219,810 $22.7 Billion

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $4.06B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Freestone Grove Partners LP Portfolio

Follow Freestone Grove Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Grove Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Grove Partners LP with notifications on news.